Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to stop lung Cancer's return

NCT ID NCT06606847

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable disease after chemoradiation and meet specific health criteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab and oleclumab (two drugs given by IV infusion)
What this could lead to
If it works, this combination could help keep stage III lung cancer from growing back after initial chemoradiation.
What could go wrong
This is a small, early-phase trial with only 30 people and no comparison group. The drugs may cause side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchial neoplasm bronchogenic carcinoma lung disorder lung neoplasm neoplasm Neoplasms by Site non-small cell lung carcinoma respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Research Site

    Kazan', 420029, Russia

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Nizhny Novgorod, 603126, Russia

  • Research Site

    Novosibirsk, 630108, Russia

  • Research Site

    Obninsk, 249031, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Ufa, 450054, Russia

  • Research Site

    Yekaterinburg, 620905, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.